BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 24563247)

  • 1. Postmarketing Surveillance of Recombinant Human Soluble Thrombomodulin (Thrombomodulin α) in Pediatric Patients With Disseminated Intravascular Coagulation.
    Shirahata A; Mimuro J; Takahashi H; Tsuji H; Kitajima I; Matsushita T; Eguchi Y; Kitamura N; Honda G; Sakata Y
    Clin Appl Thromb Hemost; 2014 Jul; 20(5):465-72. PubMed ID: 24563247
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Post-marketing surveillance of thrombomodulin alfa, a novel treatment of disseminated intravascular coagulation - safety and efficacy in 1,032 patients with hematologic malignancy.
    Asakura H; Takahashi H; Tsuji H; Matsushita T; Ninomiya H; Honda G; Mimuro J; Eguchi Y; Kitajima I; Sakata Y
    Thromb Res; 2014 Mar; 133(3):364-70. PubMed ID: 24440141
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thrombomodulin alfa treatment in patients with acute promyelocytic leukemia and disseminated intravascular coagulation: a retrospective analysis of an open-label, multicenter, post-marketing surveillance study cohort.
    Matsushita T; Watanabe J; Honda G; Mimuro J; Takahashi H; Tsuji H; Eguchi Y; Kitajima I; Sakata Y
    Thromb Res; 2014 May; 133(5):772-81. PubMed ID: 24636871
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of recombinant soluble thrombomodulin (thrombomodulin alfa) on disseminated intravascular coagulation.
    Mimuro J; Takahashi H; Kitajima I; Tsuji H; Eguchi Y; Matsushita T; Kuroda T; Sakata Y
    Thromb Res; 2013 May; 131(5):436-43. PubMed ID: 23566534
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Surveillance of the safety and efficacy of recombinant human soluble thrombomodulin in patients with obstetrical disseminated intravascular coagulation.
    Kobayashi T; Kajiki M; Nihashi K; Honda G
    Thromb Res; 2017 Nov; 159():109-115. PubMed ID: 29153952
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recombinant soluble human thrombomodulin (thrombomodulin alfa) in the treatment of neonatal disseminated intravascular coagulation.
    Shirahata A; Mimuro J; Takahashi H; Kitajima I; Tsuji H; Eguchi Y; Matsushita T; Kajiki M; Honda G; Sakata Y
    Eur J Pediatr; 2014 Mar; 173(3):303-11. PubMed ID: 24005342
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Population pharmacokinetics of thrombomodulin alfa in pediatric patients with hematological malignancy and disseminated intravascular coagulation.
    Takeuchi M; Tanoshima R; Miyagawa N; Sarashina T; Kato H; Kajiwara R; Ito S; Goto H
    Pediatr Blood Cancer; 2017 Mar; 64(3):. PubMed ID: 27734584
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recombinant human soluble thrombomodulin (thrombomodulin alfa) to treat disseminated intravascular coagulation in solid tumors: results of a one-arm prospective trial.
    Tamura K; Saito H; Asakura H; Okamoto K; Tagawa J; Hayakawa T; Aoki N
    Int J Clin Oncol; 2015 Aug; 20(4):821-8. PubMed ID: 25385713
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recombinant soluble thrombomodulin for postoperative disseminated intravascular coagulation.
    Hashimoto D; Chikamoto A; Miyanari N; Ohara C; Kuramoto M; Horino K; Ohshima H; Baba H
    J Surg Res; 2015 Aug; 197(2):405-11. PubMed ID: 25972310
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and pharmacodynamics of recombinant soluble thrombomodulin in disseminated intravascular coagulation patients with renal impairment.
    Hayakawa M; Yamamoto H; Honma T; Mukai N; Higashiyama A; Sugano M; Kubota N; Uegaki S; Sawamura A; Gando S
    Shock; 2012 Jun; 37(6):569-73. PubMed ID: 22552020
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Retrospective analysis on the clinical outcomes of recombinant human soluble thrombomodulin for disseminated intravascular coagulation syndrome associated with solid tumors.
    Ouchi K; Takahashi S; Chikamatsu S; Ito S; Takahashi Y; Kawai S; Okita A; Kasahara Y; Okada Y; Imai H; Komine K; Saijo K; Takahashi M; Shirota H; Takahashi M; Gamoh M; Ishioka C
    Int J Clin Oncol; 2018 Aug; 23(4):790-798. PubMed ID: 29511940
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation: results of a phase III, randomized, double-blind clinical trial.
    Saito H; Maruyama I; Shimazaki S; Yamamoto Y; Aikawa N; Ohno R; Hirayama A; Matsuda T; Asakura H; Nakashima M; Aoki N
    J Thromb Haemost; 2007 Jan; 5(1):31-41. PubMed ID: 17059423
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Can recombinant human thrombomodulin increase survival among patients with severe septic-induced disseminated intravascular coagulation: a single-centre, open-label, randomised controlled trial.
    Hagiwara A; Tanaka N; Uemura T; Matsuda W; Kimura A
    BMJ Open; 2016 Dec; 6(12):e012850. PubMed ID: 28039291
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of recombinant human soluble thrombomodulin in disseminated intravascular coagulation patients with acute renal dysfunction.
    Hayakawa M; Kushimoto S; Watanabe E; Goto K; Suzuki Y; Kotani T; Kiguchi T; Yatabe T; Tagawa J; Komatsu F; Gando S
    Thromb Haemost; 2017 May; 117(5):851-859. PubMed ID: 28229162
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of Combined Thrombomodulin and Antithrombin in Anticoagulant Therapy for Acute Cholangitis-induced Disseminated Intravascular Coagulation.
    Morita N; Nakahara K; Morita R; Suetani K; Michikawa Y; Sato J; Tsuji K; Ikeda H; Matsunaga K; Watanabe T; Matsumoto N; Okuse C; Suzuki M; Itoh F
    Intern Med; 2019 Apr; 58(7):907-914. PubMed ID: 30449812
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A retrospective comparative study of recombinant human thrombomodulin and gabexate mesilate in sepsis-induced disseminated intravascular coagulation patients.
    Takazono T; Nakamura S; Imamura Y; Yoshioka S; Miyazaki T; Izumikawa K; Sawai T; Matsuo N; Yanagihara K; Suyama N; Kohno S
    J Infect Chemother; 2014 Aug; 20(8):484-8. PubMed ID: 24855912
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early thrombomodulin-α administration outcome for acute disseminated intravascular coagulopathy in gastrointestinal surgery.
    Konishi H; Okamoto K; Shoda K; Arita T; Kosuga T; Morimura R; Komatsu S; Murayama Y; Shiozaki A; Kuriu Y; Ikoma H; Nakanishi M; Ichikawa D; Fujiwara H; Otsuji E
    World J Gastroenterol; 2017 Feb; 23(5):891-898. PubMed ID: 28223734
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of recombinant human soluble thrombomodulin (rhs-TM) on a rat model of disseminated intravascular coagulation with decreased levels of plasma antithrombin III.
    Aoki Y; Ohishi R; Takei R; Matsuzaki O; Mohri M; Saitoh K; Gomi K; Sugihara T; Kiyota T; Yamamoto S
    Thromb Haemost; 1994 Apr; 71(4):452-5. PubMed ID: 8052962
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Benefit Profile of Thrombomodulin Alfa Combined with Antithrombin Concentrate in Patients with Sepsis-Induced Disseminated Intravascular Coagulation.
    Murao A; Kato T; Yamane T; Honda G; Eguchi Y
    Clin Appl Thromb Hemost; 2022; 28():10760296221077096. PubMed ID: 35166576
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thrombomodulin alfa in the treatment of infectious patients complicated by disseminated intravascular coagulation: subanalysis from the phase 3 trial.
    Aikawa N; Shimazaki S; Yamamoto Y; Saito H; Maruyama I; Ohno R; Hirayama A; Aoki Y; Aoki N
    Shock; 2011 Apr; 35(4):349-54. PubMed ID: 21068698
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.